The first communication in this seriesX) described the taxonomy and fermentation of Streptomyces fradiae NRRL18158, a spontaneous mutant which was isolated from a soil sample obtained from Mexico. The fermentations ofNRRL 18159 and NRRL18160, nitrosoguanidme-induced mutants ofNRRL 18158, were also described. NRRL18158, NRRL18159, and NRRL18160 are referred to as culture A54145. This paper describes the isolation and characterization of eight acidic lipopeptide factors (A, A1? B, Bl9 C, D, E, and F) produced by culture A54145.
Materials and Methods

General Methods
UVspectra were run on a Cary model 1 18 spectrophotometer. IR spectra were recorded on a Nicolet MX-1FT-IR spectrometer. Optical rotations were determined on a Perkin-Elmer model 241 polarimeter. FABmass spectra were run on a Varian-MAT 731 or a VGAnalytical ZAB3 mass spectrometer. Amino acid analyses were performed on a Beckman model 6300 amino acid analyzer. Authentic fatty acid standards were purchased from The Foxboro Company. />-Nitrobenzyl-8 was purchased from Pierce Chemical Company.
HPLC Assay of A54145 Factors Individual A54145 factors were identified and quantitated by analytical HPLCon a DuPont Zorbax 150-C8 column (4.6 x 250mm). The mobile phase consisted of CH3CN-0.2% aq triethylamine phosphate, pH 3 (35 : 65) . With a mobile phase flow rate of 2.0 ml/minute, the following Rt's were observed for the A54145 factors: A, 12.1 minutes; Al9 13.1 minutes; B, 14.9 minutes; Bl5 13.7 minutes; C, 17.0 minutes; D, 19.6 minutes; E, 22.4 minutes; and F, 9.4 minutes.
Isolation and Purification of A54145 Factors A and F
Whole broth (4,600 liters) produced by fermentation of NRRL18159 was adjusted to pH 6.5 with f This report was presented in part at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, Oct. 23~26, 1988.
hydrochloric acid and then filtered through a filter press with 4% Celite 545. Diaion HP-20 macroreticular resin (200 liters) was added to the filtered broth and the pH was maintained at 6.0 while the broth was stirred. After 2hours the resin was collected by filtration and the filtrate was discarded. The resin was washed with water (800 liters, 35 minutes with agitation), then with CH3CN-H2O(15 : 85, 400 liters, 3 minutes with agitation) and the washes discarded. Antibacterial activity was eluted from the resin with CH3CN-H2O(1 : 1, 2 x 600 liters, 35 minutes each with agitation). The combined eluates (1,200 liters) were applied to a column containing Amberlite IRA-68 (AcO~) anion exchange resin (100 liters, equilibrated in CH3CN-H2O) which was then washed with CH3CN-H2O (500 liters) and CH3CN-0.2n HOAc(1 : 1, 300liters). The column was then eluted with additional CH3CN-0. A54145A-enriched material (1.0 g) was purified by RPHPLC on columns (2-2.2 x 30cm) packed with DuPont Zorbax ODS (12/mi) eluting with pyridine-HOAc-H2O-CH3CN-MeOH (1 : 1 : 70 : 18 : 10) at a flow rate of 9ml/minute to give A54145A (212mg). A54145F-enriched material (800mg) was purified on a column (2.2x 50cm) packed with LP-1/C18 resin (20/xm), eluting in a mobile phase consisting of pyridine-HOAc-H2O-CH3CN (1 : 1 : 65: 33) at a flow rate of 8ml/minute to give A54145F (366.2mg).
Isolation and Purification of A54145 Factors B, C, D, and E Whole broth (217 liters) produced by fermentation of NRRL18159 was filtered through a filter press with 3% Hyflo Super-Cel filter aid. The pH of the filtered broth (185 liters) was adjusted to 6.4, using 5n HC1. Diaion HP-20 macroreticular resin (20liters) was added to the filtered broth; after stirring at room temperature, the resin was collected by filtration and the filtrate was discarded. The resin was washed with water (60liters, with agitation), then with CH3CN-H2O(15 : 85, 40 liters, with agitation) and the washes discarded. Antibacterial activity was eluted from the resin with CH3CN-H2O(1 : 1, 2 x 30liters, with agitation). The combined eluates (60liters) were applied to a column containing Amberlite IRA-68 (AcO~) anion exchange resin (6.3x81cm). The effluent, CH3CN-H2Owash (1: 1, 10 liters), and CH3CN-O.I n HOAcwash (1 : 1, 10 liters) were discarded. The column was then eluted with additional CH3CN-I.ON HOAc(1 : 1, 14 liters), which was concentrated and lyophilized to give crude A54145 antibiotic complex (101.1 g).
Crude A54145 complex (60g, dissolved in 400ml of pyridine-HOAc-H2O, 1 : 1 :98) was subjected to preparative RPHPLCon an 8cmx lm column (Jobin Yvon Chromatospac Prep 100) containing Isolation and Purification of A54145 Factor A* Whole broth (103 liters) produced by fermentation of NRRL18158 was filtered and subjected to batchwise absorption/desorption with Diaion HP-20as in the example immediately above. The combined eluates were applied to a column (4.0 x 78.0cm) containing BioRad BioRex 5 (Cl~) anion exchange resin and eluted with a gradient of 0.1 n-1.0n NaCl. Fractions containing antibacterial activity were combined and desalted over a column (4 x 40cm) of Diaion HP-20. Active fractions were concentrated and lyophilized to give crude A54145 antibiotic complex (12.08g). Crude A54145 (2g) was subjected to preparative RPHPLCon a Waters PrepPak 500 C18 column; elution was accomplished with a linear gradient from H2O to CH3CN-H2O (1 : 1) buffered with 1% NH4H2PO4. A54145Ai containing fractions were combined and desalted over a Diaion HP-20 column, then repeatedly rechromatographed on columns (2-2.2 x 30cm) packed with DuPont Zorbax ODS (12^m) eluting with pyridine-HOAc-H2O-CH3CN Whole broth (100 liters) produced by fermentation of NRRL18160 was filtered and subjected to batchwise absorption/desorption with Diaion HP-20 as in the examples above. The CH3CN-H2O(15 : 85) eluate was concentrated and lyophilized to give crude antibiotic (248.2 g). A portion of crude antibiotic (60g) was subjected to preparative HPLCon an LP-1/C18 column (2.2 x 60cm). A54145Bj enriched material eluted with pyridine-HOAc-H2O-CH3CN (1 : 1 : 63 : 35) was further purified over columns (2~2.2 x 30cm) containing Amicon Matrex silica LC (C18, 10/mi) to give purified A54145BX (207mg).
Determination of TV-Acyl Substituents of A54145 Factors
The 7V-acyl substituents of the A54145 lipopeptide factors were determined by hydrolysis of the acyl group followed by derivatization of the resultant fatty acids to the /?-nitrobenzyl (PNB) esters. The HPLC Rt's were compared to those of PNBesters of authentic fatty acids using a DuPont Zorbax ODScolumn (4.6 x 250mm) and a mobile phase consisting of CH3CN-H2O (80 : 20). At a flow rate of 2.0ml/minute, the following representative Rt's were observed for PNBesters of authentic fatty acids: «-Nonanoyl-PNB ester («C9-PNB), 5.9 minutes; 8-methylnonanoyl-PNB ester (/C1 0-PNB), 7.4 minutes; rc-decanoyl-PNB ester («C10-PNB), 8.0 minutes; 8-methyldecanoyl-PNB ester (aCn-PNB), 9.9 minutes; rc-undecanoyl-PNB ester (wCn-PNB), 1 1.2 minutes; 10-methylundecanoyl-PNB ester (/C12-PNB), 14.3 minutes; and w-dodecanoyl-PNB ester («C12-PNB), 15.8 minutes.
In a typical example, A54145A(0.71 mg) was weighed into a 5-ml vacuum hydrolysis tube and 6n HC1 (1.0ml) added. The tube was evacuated and then placed in a 107°C heating block for 16hours. After cooling, CH2C12 (0.5ml) was added and the tube was shaken. CH2C12phase (0.5ml) was removed and placed into a l ml reaction vial. CH2C12(100/zl) and 0-(PNB)-A^7V'-(diisopropyl)isourea (0.1 m solution in CH2C12(Pierce^-nitrobenzyl-8), 100^1) were added and the solution stirred at 80°C for 2hours. The cooled reaction solution was blown dry under a stream ofN2, redissolved in CH3CN, and analyzed by HPLC asabove. Table  2 ).
The structure elucidation ofA541 45 lipopeptide antibiotics2) (Fig. 3) antibiotic analogs by chemical reacylation of microbially deacylated 7V-Lys-protected-A54145 complex4'5) are described in separate reports. Each A54145 factor exhibits in vitro activity (MIC 0.26~16/xg/ml) against strains of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, and Streptococcus pneumoniae6). The antibacterial activity of A54145factors and semisynthetic derivatives, resistance development studies, calcium dependency, and in vivo evaluation are reported in full in a separate publication7*.
